T
he adult human heart can lose up to a billion cardiomyocytes after a myocardial infarction, the vast majority of which are never replaced. Because of the negligible regenerative capacity of the adult heart, this initial insult causes permanent damage to the myocardium and results in a deterioration in heart function, often culminating in heart failure. 1 Regenerative therapies aim to replace the damaged myocardium to recover contractile function after injury. A number of cellular replacement therapies have been trialed for ischemic heart disease that could potentially replenish cardiomyocytes after injury. One of the most popular approaches has been the use of bone marrow-derived populations, including mesenchymal stromal cells (MSCs). MSC-like populations have also been reported in a number of other tissues, including the heart, which has raised the prospect of using cardiac resident populations for heart repair. 2 Numerous preclinical studies have reported beneficial effects of MSCs after myocardial infarction in animal models, although their cardiomyogenic potential remains controversial. MSC clinical trials for heart failure are progressing, with reports of some modest but significant improvements in heart function. 3 It is therefore important to determine the mechanisms driving the cardioprotective actions of MSCs and to further enhance their clinical utility for patients with heart failure.
The effectiveness of cellular therapies for heart disease is currently limited by poor cell retention, cell death, poor engraftment, and lack of integration in the ischemic myocardium, as well as immune clearance of the transplanted cells, all of which limit the long-term persistence of the delivered cells. As a consequence, <5% of cells are retained within the heart within a few hours after systemic injection, 4 with slightly higher retention rates achieved if intramuscular delivery is used. 5 Lack of retention potentially limits the long-term efficacy of the implanted cells after transplantation. A major cause of cell loss after implantation is anoikis, a form of apoptosis caused by lack of cell-substrate binding. Two ways to overcome anoikis are to coinject hydrogels or extracellular matrix (reviewed by Sart et al 6 ) and to incorporate cells in a 3-dimensional tissue engineered environment, 7, 8 both of which have been demonstrated to improve engraftment and survival of cells after intracardiac injection. However, improving cell retention and survival after implantation remains a major challenge for the field.
In this issue of Circulation, Bortolotti et al 9 develop a novel approach based on the functional selection (FunSel) of factors that enhance MSC retention, engraftment, and survival in vivo. This new technique is based on a method that was previously developed by the Giacca laboratory and reported by Ruozi et al 10 for screening of tissue-protective factors in skeletal muscle after ischemia. In the original study, striated muscles were infected with an arrayed library of adenoassociated viruses (AAVs) encoding secreted factors. With this approach, each cell received a different pool of factors (in principle), and if a particular factor was protective, those cells became enriched when a selective stimulus (eg, ischemia) was applied. The original method involved multiple rounds of selection and cloning to identify the protective factors, which became progressively enriched, thus enabling the identification of protective factors from hundreds of potential candidates. 10 Bortolotti et al further optimize FunSel by incorporating unique barcodes for each cDNA in the AAV library, which enables rapid identification of protective factors using next-generation sequencing and avoids the need for multiple iterative cycles of selection and cloning. Bortolotti et al use this approach to rapidly select factors that promote engraftment and survival of bone marrow-derived MSCs (BMMSCs) after myocardial ischemia in vivo from a library of 80 AAV vectors expressing different cytokines.
Using FunSel, Bortolotti et al identified 2 factors, Ctf1 (cardiotrophin-1) and Ccl2, that promoted engraftment of BM-MSCs in healthy hearts. After delivery of BM-MSCs to the infarcted myocardium, Ctf1, Fam19a3, and Ccl7 were enriched, suggesting that there may be differences between factors capable of promoting engraftment and survival in normal versus infarcted hearts. Because Ctf1 was enriched in BMMSCs injected into both healthy and infarcted hearts, the authors subsequently focused on this factor. BMMSCs infected with AAV vectors encoding Ctf1, as well as cells pretreated for 12 hours with recombinant Ctf1, exhibited increased incorporation into the myocardium and significantly improved heart function and reduced scar size up to 60 days after myocardial infarction. Thus, Ctf1 improves BM-MSC retention and further augments the therapeutic gains associated with BM-MSC delivery after myocardial infarction.
The authors subsequently focused on delineating the mechanism by which Ctf1 improves survival and engraftment of MSCs. Treatment of BM-MSCs with Ctf1 rapidly activated signal transducer and activator of transcription 3 (STAT3), which was required for activation of focal adhesion kinase complexes and BM-MSC attachment to substrates or cultured cardiomyocytes in vitro. This was sufficient to reduce activated caspase 3 and apoptosis in BM-MSCs. In addition, Ctf1 protected BM-MSCs against oxidative stress in vitro, which implanted cells may experience in damaged environments such as after myocardial infarction in vivo. The authors also found that Ctf1 elicited similar effects in adipose tissue-derived MSCs, suggesting that it could potentially enhance the retention and survival of multiple cell types.
In addition to the direct effects of Ctf1 on the retention and engraftment of BM-MSCs, a number of other potential explanations for the protective actions of Ctf1 need to be considered. Although there were no direct statistical comparisons of heart function between AAVCtf1 and recombinant Ctf1 groups, the functional benefits and reduction in scar size were seemingly higher in BM-MSCs pretreated with AAV-Ctf1 compared with those pretreated with recombinant Ctf1. This highlights the possibility that either long-term overexpression of Ctf1 in BM-MSCs is better for long-term survival of MSCs or Ctf1 has positive paracrine effects in the heart (eg, enhancing angiogenesis, enhancing cardiomyocyte survival, or augmenting cardiomyocyte proliferation). The fact that the rates of engraftment and survival of BM-MSCs after 21 and 60 days were similar between the AAV-Ctf1-infected and recombinant Ctf1 pretreatment groups suggests that the latter possibility may be important. In support of this notion, the gp130/STAT3 signaling axis, which Ctf1 activates, has been previously shown to induce ECM production in the heart and to enhance survival and proliferation of cardiomyocytes. [11] [12] [13] [14] Moreover, Ctf1 did not promote transdifferentiation of BM-MSCs into cardiomyocytes, adding further weight to a growing body of evidence suggesting that bone marrow-derived cells, including MSCs, have negligible cardiomyogenic potential. Future studies are warranted to further dissect the benefits associated with sustained versus transient Ctf1 expression in BMMSCs after transplantation into the heart. It will also be important to validate these findings in a large animal model to assess the long-term safety and efficacy of this approach before progressing to clinical trials.
The present study by Bortolotti et al demonstrates the exciting potential of FunSel for unbiased screening to find new factors that could enhance the therapeutic potential of cellular therapies. Although this study represents a relatively boutique screen of known cytokines, this approach could conceivably be expanded in the future for screening of additional factors. Given the importance of cell-substrate interactions for BM-MSC survival and engraftment, future screens could include extracellular matrix factors, which may also be very important. In addition, this approach can be readily adapted to other cell types and injury models, thus providing broad potential across the cardiovascular field. One example, which is perhaps the simplest extension of this work, would be to improve the delivery of human pluripotent stem cell-derived cardiomyocytes, which has emerged as an attractive cellular source for cardiac regeneration, 15 albeit one that is similarly hampered by issues related to cell retention and engraftment in the ischemic heart. FunSel provides a new tool in the stem cell armamentarium with the potential to significantly advance the prospects of cellular therapies for heart disease.
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